Ser511
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser511  -  TSC1 (human)

Site Information
DsPFyRDsLPGsQRK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3208191

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 18 ) , mass spectrometry ( 1 , 2 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 ) , mass spectrometry (in vitro) ( 18 ) , mutation of modification site ( 18 ) , phospho-antibody ( 3 , 18 ) , western blotting ( 3 , 18 )
Disease tissue studied:
breast cancer ( 18 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 14 ) , chronic myelogenous leukemia ( 14 ) , liver cancer ( 15 ) , liver cancer, surrounding tissue ( 16 ) , lung cancer ( 9 , 10 , 11 ) , non-small cell lung cancer ( 9 , 10 , 11 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
IKKB (human) ( 3 , 18 )
Kinases, in vitro:
IKKB (human) ( 3 , 18 )
Treatments:
angiotensin_2 ( 3 ) , Bay_11-7082 ( 18 ) , IL-1b ( 18 ) , LPS ( 18 ) , ML120B ( 3 ) , MLN8054 ( 8 ) , parthenolide ( 18 ) , siRNA ( 18 ) , TNF ( 18 )

Downstream Regulation
Effects of modification on TSC1:
molecular association, regulation ( 18 ) , phosphorylation ( 18 ) , protein degradation ( 18 ) , ubiquitination ( 18 )
Effects of modification on biological processes:
carcinogenesis, induced ( 18 ) , cell growth, induced ( 18 ) , signaling pathway regulation ( 18 )
Inhibit interaction with:
TSC2 (human) ( 18 )

Disease / Diagnostics Relevance
Relevant diseases:
breast cancer ( 18 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Doyon P, van Zuylen WJ, Servant MJ (2013) Role of IκB Kinase-β in the Growth-Promoting Effects of Angiotensin II In Vitro and In Vivo. Arterioscler Thromb Vasc Biol 33, 2850-7
24135021   Curated Info

4

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

5

Guo A (2011) CST Curation Set: 11886; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

6

Guo A (2011) CST Curation Set: 11887; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

7

Guo A (2011) CST Curation Set: 11888; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

8

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

9

Rikova K (2010) CST Curation Set: 9470; Year: 2010; Biosample/Treatment: tissue, /untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

10

Rikova K (2010) CST Curation Set: 9453; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

11

Rikova K (2010) CST Curation Set: 9460; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

12

Possemato A (2010) CST Curation Set: 9348; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)Xp[ST](I/L/V)
Curated Info

13

Possemato A (2010) CST Curation Set: 9394; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

14

Rikova K (2010) CST Curation Set: 9327; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

15

Tucker M (2010) CST Curation Set: 8912; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

16

Tucker M (2010) CST Curation Set: 8915; Year: 2010; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

17

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

18

Lee DF, et al. (2007) IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 130, 440-55
17693255   Curated Info